SCHEDULE: T. Rowe Price Boosts Entrada Therapeutics Stake

T. Rowe Price Associates, Inc. has disclosed a 6.8% beneficial ownership stake in Entrada Therapeutics Inc. common stock, held for passive investment purposes.

Summary

• T. Rowe Price Associates, Inc. reported beneficial ownership of 2,567,478 shares of Entrada Therapeutics Inc. common stock.
• This stake represents 6.8% of the total class of securities.
• The shares are held in the ordinary course of business and not for the purpose of changing or influencing the control of Entrada Therapeutics Inc.
• T. Rowe Price Associates, Inc. holds sole voting power over 2,462,803 shares and sole dispositive power over 2,548,937 shares.
• The event date requiring this filing was June 30, 2025, with the statement signed on August 14, 2025.

Sentiment

Score: 8

Explanation: The disclosure of a significant passive stake by a major institutional investor like T. Rowe Price generally signals confidence in the company's long-term prospects and can be viewed positively by the market.

Positives

• A significant 6.8% stake by a major institutional investor like T. Rowe Price Associates, Inc. signals confidence in Entrada Therapeutics Inc.'s long-term prospects.
• The investment is stated to be for passive purposes, indicating a belief in the company's current management and strategic direction without intent to interfere.

Risks

• No specific company-level risks are detailed in this beneficial ownership disclosure.
• The reporting person, T. Rowe Price Associates, Inc., explicitly denies beneficial ownership of the securities, stating that the filing of Schedule 13G shall not be construed as an admission of such ownership.

Future Outlook

No forward-looking statements or guidance regarding Entrada Therapeutics Inc.'s future performance or strategy are provided in this beneficial ownership disclosure.

Management Comments

• Securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.
• Filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

Industry Context

The disclosure highlights continued institutional interest in the biotechnology sector, with a major asset manager like T. Rowe Price taking a significant passive stake in a therapeutics company.

Stakeholder Impact

• Shareholders: The presence of a large, passive institutional investor can provide stability and a vote of confidence, potentially attracting further investment.

Key Dates

Recommendation

This Schedule 13G filing primarily provides transparency on institutional ownership and does not contain sufficient financial or operational details to form a comprehensive buy or sell recommendation. The presence of a significant institutional investor like T. Rowe Price is a positive indicator, suggesting a degree of confidence, but it does not inherently warrant a change in investment posture without further analysis of the company's fundamentals and strategic direction.

Keywords

Entrada Therapeutics, T. Rowe Price, institutional ownership, Schedule 13G, common stock, biotechnology, passive investment